CIK 0001439222 · Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-06 | Foster-Cheek Kaye I Director | Sale | −4,415 | $31.99 | $141K | 6,809 |
| 2024-03-05 | Foster-Cheek Kaye I Director | Sale | −300 | $32.21 | $10K | 11,224 |
| 2024-03-05 | Washburn Theodore James Jr. Principal Accounting Officer | Sale | −1,913 | $31.75 | $61K | 2,886 |
| 2024-03-05 | Gheuens Sarah Chief Medical Officer | Sale 10b5-1 | −1,293 | $32.57 | $42K | 36,415 |
| 2024-03-05 | Gheuens Sarah Chief Medical Officer | Sale 10b5-1 | −1,349 | $32.57 | $44K | 39,066 |
| 2024-03-05 | Jones Cecilia Chief Financial Officer | Sale 10b5-1 | −672 | $32.57 | $22K | 14,840 |
| 2024-03-05 | Washburn Theodore James Jr. Principal Accounting Officer | Sale 10b5-1 | −295 | $32.57 | $10K | 3,368 |
| 2024-03-05 | Washburn Theodore James Jr. Principal Accounting Officer | Sale 10b5-1 | −919 | $32.57 | $30K | 4,799 |
| 2024-03-05 | Goff Brian Chief Executive Officer | Sale 10b5-1 | −4,156 | $32.57 | $135K | 53,780 |
| 2024-03-05 | Burns James William Chief Legal Officer | Sale 10b5-1 | −1,293 | $32.57 | $42K | 34,518 |
| 2024-03-05 | Burns James William Chief Legal Officer | Sale 10b5-1 | −1,349 | $32.57 | $44K | 37,169 |
| 2024-03-01 | Gheuens Sarah Chief Medical Officer | Option exercise 10b5-1 | +3,834 | 37,708 | ||
| 2024-03-01 | Gheuens Sarah Chief Medical Officer | Option exercise 10b5-1 | +4,000 | 40,415 | ||
| 2024-03-01 | Gheuens Sarah Chief Medical Officer | Grant or award · Restricted stock units 10b5-1 | +17,000 | 17,000 | ||
| 2024-03-01 | Gheuens Sarah Chief Medical Officer | Grant or award · Stock options (right to buy) 10b5-1 | +60,000 | 60,000 | ||
| 2024-03-01 | Gheuens Sarah Chief Medical Officer | Option exercise · Restricted stock units 10b5-1 | −3,834 | 3,833 | ||
| 2024-03-01 | Gheuens Sarah Chief Medical Officer | Option exercise · Restricted stock units 10b5-1 | −4,000 | 8,000 | ||
| 2024-03-01 | Jones Cecilia Chief Financial Officer | Option exercise 10b5-1 | +2,000 | 15,512 | ||
| 2024-03-01 | Jones Cecilia Chief Financial Officer | Grant or award · Restricted stock units 10b5-1 | +17,000 | 17,000 | ||
| 2024-03-01 | Jones Cecilia Chief Financial Officer | Grant or award · Stock options (right to buy) 10b5-1 | +60,000 | 60,000 |
Page 22 of 48 · 941 trades